**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 52710

**Manuscript Type:** OPINION REVIEW

**Global whole family based-*Helicobacter pylori* eradication strategy to prevent its related diseases and gastric cancer**

Ding SZ. A whole family based-*H. pylori* eradication strategy

Song-Ze Ding

**Song-Ze Ding,** Department of Gastroenterology and Hepatology, People’s Hospital of Zhengzhou University, Henan Provincial People’s Hospital, and Henan University School of Medicine, Zhengzhou 450003, Henan Province, China

**Author contributions:** Ding SZ designed the overall concept and outline of the manuscript; completed the writing, editing the manuscript, illustrations, and review of literature.

**Supported by** grants to SZD from Henan Provincial Government-Science and Technology Bureau, No. 142300410050; Henan Provincial Government-Health and Family Planning Commission, No. 20170123; Henan Provincial Innovative Talents Projects of 2016 and 2017; National Natural Science Foundation of China, No. U1604174.

**Corresponding author:** **Song-Ze Ding, MD, PhD, Chief Doctor, Full Professor,** Department of Gastroenterology and Hepatology, Henan Provincial People’s Hospital, Zhengzhou University, No. 7 Wei Wu Road, Jin Shui District, Zhengzhou 450003, Henan Province, China. dingsongze@hotmail.com

**Received:** November 14, 2019

**Revised:** December 14, 2019

**Accepted:** February 12, 2020

**Published online:** March 14, 2020

**Abstract**

*Helicobacter pylori* (*H. pylori*) infects approximately 50% of the world population. The multiple gastrointestinal and extra-gastrointestinal diseases caused by *H. pylori* infection pose a major healthcare threat to families and societies; it is also a heavy economic and healthcare burden for countries that having high infection rates. Eradication of *H. pylori* is recommended for all infected individuals. Traditionally, “test and treat” and "screen and treat" strategies are available for various infected populations. However, clinical practice has noticed that these strategies have some shortfalls and may need refinement, mostly due to the fact that they are not easily manageable, and are affected by patient compliance, selection of treatment population and cost-benefit estimations. Furthermore, it is difficult to control infections from the source, and so the development of additional, compensative strategies are therefore encouraged to solve the above problems and facilitate bacteria eradication. *H. pylori* infection is a family-based disease, but few studies have been performed in a whole family-based approach to curb its intra-familial transmission and the development of related diseases. In this work, a third, novel whole family-based *H. pylori* eradication strategy is introduced. This approach screens, identifies, treats and follows up on all *H. pylori*-infected individuals in entire families to control *H. pylori* infection among family members, and reduce its long-term complications. This strategy is high-risk population-oriented, and able to reduce *H. pylori* spread among family members. It also has good patient-family compliance and, importantly, is practical for both high and low *H. pylori*-infected communities. Future efforts in these areas will be critical to initiate and establish healthcare policies and management strategies to reduce *H. pylori*-induced disease burden for society.

**Key words:** *Helicobacter pylori*; Intra-familial infection; Gastrointestinal disease; Gastric cancer

Ding SZ. Global whole family based-*Helicobacter pylori* eradication strategy to prevent its related diseases and gastric cancer. *World J Gastroenterol* 2020; 26(10): 995-1004

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i10/995.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i10.995

**Core tip:** *Helicobacter pylori* (*H. pylori*)infection is an infectious and family-based disease. In additional to “test and treat” and "screen and treat" strategies, this work introduces a novel, “whole family-based *H. pylori* eradication strategy” to screen, identify, treat and follow up on all *H. pylori*-infected family members within a family unit. This “whole family- or household-based strategy” is high-risk and population-oriented, and will be able to reduce *H. pylori* spread among family members with good patient-family compliance. Importantly, this strategy is practical for both high and low *H. pylori*-infected communities.

**INTRODUCTION**

*Helicobacter pylori* (*H. pylori*) infection, the major cause of chronic gastritis, peptic ulcers and gastric cancer, infects approximately 50% of the world population, and is also closely associated with many extra-gastrointestinal diseases. These include idiopathic thrombocytopenic purpura, iron deficiency anemia, vitamin B12 deficiency, autoimmunity diseases, heart and cerebrovascular diseases, *etc*[[1](#_ENREF_1),[2](#_ENREF_2)]. The latest cancer statistics in 2018 noted that gastric cancer is the fifth most frequently diagnosed cancer and third leading cause of cancer deaths worldwide[[3](#_ENREF_3)]. *H. pylori* eradication has been set as a strategy for preventing gastric cancer by IARC/WHO in 2014[[4](#_ENREF_4)]. Population-based observation, systematic review and meta-analyses have demonstrated that *H. pylori* eradication can lead to reduction in the incidence of gastric-related disease and cancer, depending on the severity and extent of damage at the time of eradication[[5-8](#_ENREF_5)].

Although there are huge number of people infected, and international consensus reports have clearly indicated its urgency[[1](#_ENREF_1),[2](#_ENREF_2),[9](#_ENREF_9),[10](#_ENREF_10)], the slowly progressing nature of *H. pylori* does not immediately result in losing labor or disturbing society’s stability. Thus, the prevention and eradication of *H. pylori* infection in most countries has yet to receive attention to the extent of other common infectious diseases, including tuberculosis, human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection. The financial and healthcare burden could be fairly heavy if all the costs of *H. pylori*-related treatment sand hospital expenses are added up. Approximately 30% of infected persons will develop various kinds of diseases, such as dyspepsia, gastritis, peptic ulcers, atrophic gastritis, intestinal metaplasia, gastric malignancies and multiple extra-gastrointestinal diseases[[10](#_ENREF_10)]. Therefore, developing novel healthcare policies or management strategies for prevention, treatment, education and improving public awareness of its hazardous effects will be critical for reducing the *H. pylori-*related disease burden in society.

**WHOLE FAMILY *H. PYLORI* INFECTION, INTRA-FAMILIAL TRANSMISSION AND DISEASE PROGRESSION**

The Kyoto global consensus report on *H. pylori* gastritis in 2015 indicated that *H. pylori* gastritis is an infectious disease. All infected persons will have different degrees of gastritis, and eradication of *H. pylori* removes the reservoir of infection, reduces the incidence of infection, and prevents severe complications[[2](#_ENREF_2)]. Other guidelines including management of *H. pylori* infection, the 2017 Maastricht V/Florence Consensus report, and guidelines from the United States, China, Japan, and Asia-pacific, as well as several large clinical observations, have also proposed that eradication of *H. pylori* before gastric mucosal atrophy and intestinal metaplasia can reduce the risk of gastric cancer. Furthermore, they recommended the treatment of all *H. pylori*-infected patients[[1](#_ENREF_1),[5-12](#_ENREF_5)]. We have further proposed a strategy in China to “screen, identify, treat and follow up on all *H. pylori*-infected individuals in the entire family. This is to prevent *H. pylori* spreading among family members in order to reduce infection and its long-term complications", as infected family members are always a risk source for transmission[[13](#_ENREF_13)] (Table 1).

Increasing evidence has demonstrated that *H. pylori* can be found in various environments, including water and food products for the family[[14-19](#_ENREF_14)]. *H. pylori* is primarily transmitted by oral-oral and fecal-oral routes. Intra-familial spreading is a major form of *H. pylori* infection[[12](#_ENREF_12),[20](#_ENREF_20)]; the bacterium has been cultivated from vomitus, saliva and cathartic stool from infected persons, and was detected in dental plaques and cavities[[1](#_ENREF_1),[21](#_ENREF_21)]. Furthermore, the bacterium can survive in milk, ready-to-eat foods, vegetables, juices, and meats for certain periods of time. It was also detected in various family food products such as water, vegetables, and different sources of meat as reviewed by Quaglia and Dambrosio[[14](#_ENREF_14)]. *H. pylori* was also detected and isolated from animal gastric mucosa such as sheep and cows[[15](#_ENREF_15),[16](#_ENREF_16)]. Its presence in drinking water, freshwater, well water, estuarine, seawater and marine products were reported by using either molecular methods or bacteriological culture[[14](#_ENREF_14),[17-19](#_ENREF_17)]. Despite needing further confirmation, this information clearly suggests that these are all potential sources of infection and are possible transmission routes within a family (Table 2). *H. pylori* infection is therefore speculated to be a foodborne or waterborne disease, with humans and animals as the likely reservoir[[14](#_ENREF_14)].

Studies have shown that most *H. pylori* infections occur in childhood, and are less common in adulthood; intra-familial transmission is the major path for *H. pylori* infection for children, mainly spread by parents, especially mothers[[12](#_ENREF_12),[20](#_ENREF_20),[22](#_ENREF_22)]. The common routes of infection among family members include sharing food from the same dish, food ware, dental equipment, chewing food feeding, kissing, poor hygiene practice *etc.* After infection early in life, the chronic gastritis slowly progress for years following Correa cascade, namely chronic gastritis, atrophy, intestinal metaplasia, intraepithelial neoplasia, and gastric cancer. This in turn results in the above disease presentations at adulthood[[1](#_ENREF_1),[2](#_ENREF_2)]. In addition, various factors affect intra-familial transmission such as religion, location, ethnicity, living habits, social-economic status, and family size[[2](#_ENREF_2),[9](#_ENREF_9),[10](#_ENREF_10)]. Infection tends to begin before the age of 12, and the Kyoto consensus report statements 16 and 17 therefore recommend that screening and treating *H. pylori* infection be initiated after 12 years of age in various *H. pylori*-infected areas to prevent subsequent atrophy and intestinal metaplasia[[2](#_ENREF_2)]. In recent years, Japan and South Korea have begun a nation-wide *H. pylori* eradication program to reduce the incidence of gastric cancer and related diseases, therefore saving on future medical expenses[[23](#_ENREF_23),[24](#_ENREF_24)].

Multiple surveys have confirmed that the prevalence of *H. pylori* infection in childhood steadily increases with age, but with variations that depend on geographic areas and countries[[12](#_ENREF_12),[25](#_ENREF_25),[26](#_ENREF_26)]. A recent survey of 1,634 endoscopy-examined pediatric patients in Shanghai, China revealed that in children less than 3 years, 4-6 years, 7-10 years, and 11-18 years groups, the infection rates were 24.6%, 27.2%, 32.9%, and 34.8%, respectively[[25](#_ENREF_25)]. Another study in healthy school children noted a slightly higher infection rate with an average annual rate increase of 3.28% in Saudi Arabia[[27](#_ENREF_27)]. Children whose parents are infected with *H. pylori* have much higher infection rates than children whose parents are not infected[[12](#_ENREF_12)], suggesting that intra-familial transmission plays an important role in *H. pylori* transmission. However, child infection rates in North America, parts of Europe and Japan remain very low (1.8%-10%)[[22](#_ENREF_22),[26](#_ENREF_26),[28](#_ENREF_28)].

Gastric atrophy is also noticed in children and even found in very young children, and earlier small-sized study had indicated that atrophy was present in 0-72% of the samples studied, as summarized by Dimitrov and Gottrand[[29](#_ENREF_29)] in 2006. Recent studies revealed that its prevalence in various countries may correspond to the infection rate at adulthood. Studies in Chinese, Japanese, and Mexican children revealed that atrophy was present in 21.7% (among 524 cases), 10.7% (among 131 cases), and 9% (7 out of 82 cases) of children infected with *H. pylori,* respectively[[25](#_ENREF_25),[30](#_ENREF_30),[31](#_ENREF_31)]; intestinal metaplasia was present in 6% of *H. pylori-*infected Mexican children[[30](#_ENREF_30)]. In another study in Tunisian children, an area with a high infection rate, gastric atrophy was detected in 9.3% (32 out of 345 cases) of the total study population, and in 14.5% (32 out of 221 cases) of chronic gastritis patients[[32](#_ENREF_32)]. However, atrophy was not found in 96 cases of Brazilian children studied, and was rare in 66 cases of French children infected with *H. pylori*[[33](#_ENREF_33),[34](#_ENREF_34)]. Although further investigation is necessary, these data point out the possibility that atrophy and intestinal metaplasia are probably more common and are presented in similar ways to adulthood infection. Thus, active intervention based on infection situations are warranted. However, its natural course and consequences, risk potential for cancer, and factors that contribute to atrophy remain to be studied.

Management of *H. pylori* infection in children is recommended based on risk-benefit ratios. Depending on different locations and infection rates, the joint ESPGHAN/NASPGHAN guidelines for the management of *H. pylori* in children and adolescents (Update 2016) recommended against a ‘‘test and treat’’ strategy for *H. pylori* infection in children, but recommend testing and treating *H. pylori* in children with gastric or duodenal ulcer diseases[[28](#_ENREF_28)]. Guidelines provide recommendations primarily based on and for the setting of North America and Europe, which have very low and decreasing *H. pylori* infection rates. It therefore may not apply to other parts of the world that have high *H. pylori* infection rates in children and adolescents, and to those areas with only limited resources for healthcare.

In countries where *H. pylori* infection and gastric cancer are prevalent, such as in Asia, the Middle East, part of Europe, Africa, Latin American and in many developing countries, a “screen and treat” strategy to eradicate *H. pylori* infection for gastric cancer prevention is encouraged, as it is cost-effective[[9](#_ENREF_9),[10](#_ENREF_10),[22-24](#_ENREF_22)]. Similar to this notion, the 2016 Japanese-revised guidelines for the management of *H. pylori* infection recommend eradicating *H. pylori* for adolescence in order to control infection for the next generation (6.2.2. Recommendation: 1, Evidence level: B). It also suggests that “undergoing eradication therapy before becoming a parent can be a measure against transmission to the next generation by preventing intra-familial infection”[[12](#_ENREF_12)]. In the Bangkok consensuses report of 2018, the *H. pylori* management in ASEAN, Statement 4 recommended that “eradication of *H. pylori* reduces the risk of gastric cancer, and family members of gastric cancer patients should be screened and treated”[[9](#_ENREF_9)]. These guidelines provided the notion that family infection control is a critical step in *H. pylori*-induced disease prevention. Future investigations are warranted to obtain data and formulate policies for whole family-based *H. pylori* eradication. Precautions should be excised to avoid over-testing uninfected or missing infected individuals. Urease breath tests and serological or stool antigen tests might be cost-effective and efficient applications.

One concern in *H. pylori* transmission prevention is its re-infection or recrudesces after eradication, and studies have shown various results in different geographic areas that have slightly different outcomes, ranging from 0-10%[[9](#_ENREF_9),[35-37](#_ENREF_35)]. In a medium prevalence area, a study found that 1-year and 3-year recurrence rates of *H. pylori* infection in adults after eradication therapy were 1.75% and 4.61%, respectively; low income and poor hygiene condition are independent risk factors of recurrence[[35](#_ENREF_35)]. A systemic review noted that global annual recurrence, reinfection and recrudescence rates of *H. pylori* were 4.3% (95%CI: 4-5), 3.1% (95%CI: 2-5) and 2.2% (95%CI: 1-3), respectively[[36](#_ENREF_36)]. This variation also depends on the country, as one Korean study indicated that the long-term (37.1 mo) average reinfection rate was 10.9%, and the annual reinfection rate was 3.51%[[37](#_ENREF_37)]. However, few reports studied whether there was any difference when only the infected individual *versus* the entire infected family was treated.

A small observational study by Sari *et al*[[38](#_ENREF_38)] in 2008 in Turkey found that out of 70 patients with whole family (175 members) *H. pylori* testing and eradication, the recurrence rate was 7.1% 9 mo after treatment. In another 70 patients, as a control, when only the infected patient was eradicated but the whole family (190 members) infection was not treated, the recurrence rate was 38.6% 9 mo after treatment. These results suggest that treatment of the whole infected family is of great value in controlling *H. pylori* re-infection and preventing recurrence. There are currently no similar large-scale observational studies on this, and results from such studies will provide important information in guiding comprehensive prevention of *H. pylori* infection in a whole family-based approach. They will also serve as part of “precision and integrated *H. pylori* eradication medical practice”, as it has also been suggested that eradication of gastric cancer is now both possible and practical[[39](#_ENREF_39)], and that gastric cancer is a preventable disease[[40](#_ENREF_40)] through *H. pylori* eradication.

**WHY DO WE NEED THIS STRATEGY? THE MECHANISM: *H. PYLORI* VIRULENCE FACTORS AND GASTRIC CANCER**

*H. pylori* infection in whole families is often caused by the same or variant strains spreading among family members, but there are also multiple-strain infections, indicating that outside sources are also involved[[20](#_ENREF_20),[41](#_ENREF_41),[42](#_ENREF_42)]. Further studies are therefore required to clarify the importance of both routes. The whole family cluster infection model can also explain the facts that single or multiple members of the infected family have gastric mucosal pre-cancerous lesions and gastric cancer at different periods of time in their life, suggesting that co-infection, not hereditary factors, plays a more important role in disease progression.

How and why long-term *H. pylori* infection results in the development of pre-cancerous conditions and cancer remains to be defined[[43-48](#_ENREF_43)]. Upon infection, *H. pylori* triggers numerous cellular inflammatory and oncogenic signaling pathways, with list expanding, which includes but is not limited to NF-κB, AP-1, TGF-β, Wnt, Stat3, and p53 pathways *etc*. It also causes either genetic or epigenetic changes in various cell types[[43](#_ENREF_43),[47](#_ENREF_47),[48](#_ENREF_48)]. Bacterial and host factors are both involved in initiating chronic inflammatory processes, which impact host epithelial cells, immune cells, fibroblasts, stem cells and their interacting microenvironment. This results in disturbing critical cellular events including cell division, proliferation, apoptosis, migration and DNA repair, and ultimately causes cellular and oncogenic transformation[[43](#_ENREF_43),44,47,48]. Recent studies on interactions of *H. pylori* with Lgr5, CCK2R-positive gastric stem cells, or their progenitor cells and their microenvironment have shed light on the possible role of *H. pylori* on atrophic gastritis, intestinal metaplasia and gastric cancer. *H. pylori* strains carrying *cag*PAI with CagA and VacA positivity are also important for these processes[[43-48](#_ENREF_43)].

*H. pylori* cytotoxins CagA and VacA are major virulence factors and are the molecular basis for disease pathogenesis, despite that *H. pylori* possesses other virulence factors. These include outer membrane proteins, outer inflammatory proteins, and duodenal ulcer-promoting factors[[9](#_ENREF_9),[43](#_ENREF_43),[47](#_ENREF_47),48]. *H. pylori* strains that carry *cag*PAI with CagA and VacA positivity cause severe gastric inflammation, which are prone to either tissue damage or neoplastic transformation, are high-risk strains of gastric cancer, and the role of the CagA protein is critical in these processes[[48-51](#_ENREF_48)]. A few important experiments have provided evidence: *in vivo* experiments in *cagA* transgenic mice using artificially synthesized whole sequences of the *cagA* gene resulted in the development of gastric cancer and other gastrointestinal and hematological tumors in mice without *H. pylori* infection. This suggests that it has oncogenic characteristics[[49](#_ENREF_49)], and that mutation in *cagA* abolish the tumor-initiating effects in animal models[[50](#_ENREF_50)]. CagA- and VacA-positive strains are the major global forms of *H. pylori* infection, corresponding to their high prevalence in pre-cancerous lesions and gastric cancer incidences[[51](#_ENREF_51)].

Gastric cancer includes intestinal and diffuse types according to Lauren classification. Intestinal types of gastric cancer generally have distinct ductal structures, which are more common in older men and manifest with a Correa carcinogenesis pattern. Diffuse types of gastric cancer include diffuse growths, closely related to genetic inheritance, are more common in young women, and are prone to lymph nodes and distant metastasis, but both types of gastric cancer are closely related to *H. pylori* infection[[52](#_ENREF_52)]. *H. pylori*-negative gastric cancers are rare in Japan[[53](#_ENREF_53)], and may also be the case in other parts of highly infected areas if strict population-based observation are conducted. Although other factors, except in a small portion of genetically-related gastric cancers, such as lifestyle, diet, chemical factors, high salt, and changes in stomach flora or microecology, may also be involved in the occurrence and development of gastric cancer. Current comprehensive results from epidemiology, basic, clinical and population-based observations have demonstrated that *H. pylori* infection remains the single most important pathogenic factor for gastric cancer initiation and development[[1](#_ENREF_1),[9](#_ENREF_9),[43](#_ENREF_43),[47](#_ENREF_47)].

**ERADICATION OF *H. PYLORI* INFECTION IN A WHOLE FAMILY-BASED APPROACH AND FUTURE PERSPECTIVES**

The most efficient way to control *H. pylori* infection would be a specific vaccine; however, the development of an *H. pylori* vaccine has suffered setbacks, and is still in the laboratory testing stage[[54](#_ENREF_54)], so there is no hope for a clinical application in the next 5-6 years.

Traditionally, two strategies are available in the management of *H. pylori* infection: (1) “test and treat” is recommended for young patients with uninvestigated dyspepsia, but not applicable to patients with alarm symptoms or older patients; and (2) "screen and treat" is for patients with a family history of gastric cancer, having alarm symptoms and localized in gastric cancer-prevalent areas[[1](#_ENREF_1),[9](#_ENREF_9),[10](#_ENREF_10)]. In Western countries, the population-based *H. pylori* test and treatment strategies benefits may be small due to low and declining *H. pylori* infection rates, and very low rates of related diseases such as peptic ulcers, pre-cancerous lesions and gastric cancer. For other areas, such as Asia, the Middle East, part of Europe, Africa, Latin American and in many developing countries that have high infection rates and related diseases, it is beneficial, cost-effective, and worth population-based screening and intervention (Table 1)[[1](#_ENREF_1),[2](#_ENREF_2),[9](#_ENREF_9),[10](#_ENREF_10),[12](#_ENREF_12)].

These two important strategies provide general guidelines for managing *H. pylori* infection, and will continue guiding the global *H. pylori* eradication program. However, clinical applications have found that they have some shortfalls and may need refinement, mostly due to the fact that they are not easily manageable during practice, and are affected by patient compliance, selection of treatment population, cost-benefit estimation, and that infections are difficult to control from the source (Table 1)[[1](#_ENREF_1),[9](#_ENREF_9),[10](#_ENREF_10)]. In addition, they focus on treating individual patients, and do not emphasize screening and eradicating an entire family of infected members. The advantage of this approach is that they solve the problem of visiting patients, but do not underscore subsequent reinfection and continued infection by other infected family members; nor do they address issues of non-visiting, untreated, but infected family members. This practice also does not integrate associated gastric mucosal lesions, and disease progression that was already present in the infected family members. In the long run, due to the dynamic and progressive nature of infection, it is difficult to control *H. pylori* infections from the source, and subsequently increases healthcare burden at later stages of disease. Therefore, a whole family-based eradication strategy would provide help in resolving the above-mentioned problems as an additional approach. For example, “screen, identify, treat whole family infected members and follow up” would be suitable for both scenarios, as the attention and resource could be concentrated and shifted to the high-risk portion of the population for disease prevention and intervention, therefore relieving overall healthcare burden at later stages[[13](#_ENREF_13)] (Figure 1).

The superiority of whole family-based strategies over population- or community-based strategies is that they actively screen and treat infected individuals or families, which is a high-risk infection population, and family members that have high stakes are easily motivated and engaged. This makes it easier to monitor infected patients for pre-cancerous lesions and follow-ups[[13](#_ENREF_13)]. Preliminary results in practice in a whole family-based setting suggest that patients and family members have high satisfactory rates and good compliance, which deserves further investigation and refinement[[13](#_ENREF_13)]. One concern for this strategy is that it might over-screen family members that are not infected. However, as non-invasive serological tests, urease breath tests, and stool antigen tests are more affordable, accessible and efficient, this strategy provides a practical solution for whole family *H. pylori* infection screening and eradication, especially for high-risk populations (Figure 1).

*H. pylori* drug resistance is another concern for massive eradication, as the drug resistance conditions are related to local bacterial resistance patterns and previous antibiotic intake, so the guidelines are not generalizable for every country. Current guidelines recommend regimens including proton pump inhibitor-based triple and quadruple therapies[1,9,10]. They should be applied to the whole family eradication setting, and susceptibility tests either by *H. pylori* cultures or molecular biology assays are recommended for certain clarithromycin-, levofloxacin-, and metronidazole-resistant regions as well as first-time failed patients. Notably, *H. pylori* resistance to amoxicillin, tetracycline and furazolidone is very weak[1,9,10]. Safety and benefits for children during eradication have to be carefully considered during individual practice based on local infection status[[28](#_ENREF_28)].

Serological markers for detecting gastric pre-cancerous lesions and gastric cancer are currently not available, so searching and validating such candidate markers are important and urgent future working directions. The available alternative assays such as pepsinogen (Pg) I, II and anti-*H. pylori* antibody testing are instrumental for identifying patients at increased risk for gastric cancer. However, the PgI/PgII ratio should not be used as a biomarker of gastric neoplasia as recommended[[1](#_ENREF_1)]. Genotyping for *H. pylori* virulence strains involve testing CagA- and VacA-positive strains as high-risk serological markers. Furthermore, gastrin testing, pepsinogen testing and gastroscopy in a clinical setting are currently the most useful approaches for gastric lesion screening and diagnosis. These provide feasible ways to identify high-risk populations and detect early gastric pre-cancerous lesions and cancer.

**CONCLUSION**

*H. pylori* infection is an infectious disease and family-based disease. In addition to “test and treat” and "screen and treat" strategies, adoption of a third, novel whole family-based *H. pylori* infection prevention and intervention strategy as an additional approach has been described here. This new strategy can screen, identify, treat and follow up on all high-risk family members, and will prevent or reduce the risk of bacterial transmission, gastric mucosal lesion progression and gastric cancer incidence, while saving on medical costs for later stages. This “whole family- or household-based *H. pylori* precision and integrative eradication strategy” will be practical not only for highly infected communities, but also for those with low infection rates. Therefore, after proper refinement and debate, this strategy will be an important way to help reduce the source of transmission, improve public awareness of infection, and ameliorate *H. pylori* infection-related disease and gastric cancer burden for society.

**ACKNOWLEDGEMENTS**

The author is grateful to the staffs of the Department of Gastroenterology and Hepatology, People’s Hospital of Zhengzhou University for their valuable assistance with this work.

**REFERENCES**

1 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

2 **Sugano K**, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. *Gut* 2015; **64**: 1353-1367 [PMID: 26187502 DOI: 10.1136/gutjnl-2015-309252]

3 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

4 **IARC Helicobacter pylori Working Group**. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer 2014; IARC Working Group Reports. Available from: http://www.iarc.fr/en/publications/pdfsonline/wrk/wrk8/index.php

5 **Wong BC**, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA* 2004; **291**: 187-194 [PMID: 14722144 DOI: 10.1001/jama.291.2.187]

6 **Lee YC**, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. *Gastroenterology* 2016; **150**: 1113-1124.e5 [PMID: 26836587 DOI: 10.1053/j.gastro.2016.01.028]

7 **Lee YC**, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. *Gut* 2013; **62**: 676-682 [PMID: 22698649 DOI: 10.1136/gutjnl-2012-302240]

8 **Pan KF**, Zhang L, Gerhard M, Ma JL, Liu WD, Ulm K, Wang JX, Zhang L, Zhang Y, Bajbouj M, Zhang LF, Li M, Vieth M, Liu RY, Quante M, Wang LH, Suchanek S, Zhou T, Guan WX, Schmid R, Classen M, You WC. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. *Gut* 2016; **65**: 9-18 [PMID: 25986943 DOI: 10.1136/gutjnl-2015-309197]

9 **Mahachai V**, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. *J Gastroenterol Hepatol* 2018; **33**: 37-56 [PMID: 28762251 DOI: 10.1111/jgh.13911]

10 **Liu WZ**, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. *Helicobacter* 2018; **23**: e12475 [PMID: 29512258 DOI: 10.1111/hel.12475]

11 **Fallone CA**, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. *Gastroenterology* 2016; **151**: 51-69.e14 [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006]

12 **Kato M**, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, Suzuki H, Handa O, Furuta T, Mabe K, Murakami K, Sugiyama T, Uemura N, Takahashi S. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. *Helicobacter* 2019; **24**: e12597 [PMID: 31111585 DOI: 10.1111/hel.12597]

13 **Ding SZ**. [Focusing on whole family based-*Helicobacter pylori* infection management and clinical research to prevent gastric mucosal diseases and gastric cancer]. *Zhonghua Yi Xue Za Zhi* 2019; **99**: 1446-1448 [PMID: 31137135 DOI: 10.3760/cma.j.issn.0376-2491.2019.19.003]

14 **Quaglia NC**, Dambrosio A. *Helicobacter pylori*: A foodborne pathogen? *World J Gastroenterol* 2018; **24**: 3472-3487 [PMID: 30131654 DOI: 10.3748/wjg.v24.i31.3472]

15 **Momtaz H**, Dabiri H, Souod N, Gholami M. Study of Helicobacter pylori genotype status in cows, sheep, goats and human beings. *BMC Gastroenterol* 2014; **14**: 61 [PMID: 24708464 DOI: 10.1186/1471-230X-14-61]

16 **Dore MP**, Sepulveda AR, El-Zimaity H, Yamaoka Y, Osato MS, Mototsugu K, Nieddu AM, Realdi G, Graham DY. Isolation of Helicobacter pylori from sheep-implications for transmission to humans. *Am J Gastroenterol* 2001; **96**: 1396-1401 [PMID: 11374673 DOI: 10.1111/j.1572-0241.2001.03772.x]

17 **Holman CB**, Bachoon DS, Otero E, Ramsubhag A. Detection of Helicobacter pylori in the coastal waters of Georgia, Puerto Rico and Trinidad. *Mar Pollut Bull* 2014; **79**: 354-358 [PMID: 24332757 DOI: 10.1016/j.marpolbul.2013.11.021]

18 **Abdel-Moein KA**, Saeed H, Samir A. Novel detection of Helicobacter pylori in fish: A possible public health concern. *Acta Trop* 2015; **152**: 141-144 [PMID: 26364719 DOI: 10.1016/j.actatropica.2015.09.005]

19 **Moreno Y**, Ferrús MA. Specific detection of cultivable Helicobacter pylori cells from wastewater treatment plants. *Helicobacter* 2012; **17**: 327-332 [PMID: 22967115 DOI: 10.1111/j.1523-5378.2012.00961.x]

20 **Kivi M**, Tindberg Y, Sörberg M, Casswall TH, Befrits R, Hellström PM, Bengtsson C, Engstrand L, Granström M. Concordance of Helicobacter pylori strains within families. *J Clin Microbiol* 2003; **41**: 5604-5608 [PMID: 14662948 DOI: 10.1128/jcm.41.12.5604-5608.2003]

21 **Parsonnet J**, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. *JAMA* 1999; **282**: 2240-2245 [PMID: 10605976 DOI: 10.1001/jama.282.23.2240]

22 **Okuda M**, Lin Y, Kikuchi S. Helicobacter pylori Infection in Children and Adolescents. *Adv Exp Med Biol* 2019; **1149**: 107-120 [PMID: 31037557 DOI: 10.1007/5584\_2019\_361]

23 **Asaka M**, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. *J Gastroenterol* 2014; **49**: 1-8 [PMID: 24162382 DOI: 10.1007/s00535-013-0897-8]

24 **Koh JS**, Joo MK. *Helicobacter pylori* eradication in the treatment of gastric hyperplastic polyps: beyond National Health Insurance. *Korean J Intern Med* 2018; **33**: 490-492 [PMID: 29724084 DOI: 10.3904/kjim.2018.122]

25 **Yu Y**, Su L, Wang X, Wang X, Xu C. Association between Helicobacter pylori infection and pathological changes in the gastric mucosa in Chinese children. *Intern Med* 2014; **53**: 83-88 [PMID: 24429445 DOI: 10.2169/internalmedicine.53.0918]

26 **Okuda M**, Osaki T, Lin Y, Yonezawa H, Maekawa K, Kamiya S, Fukuda Y, Kikuchi S. Low prevalence and incidence of Helicobacter pylori infection in children: a population-based study in Japan. *Helicobacter* 2015; **20**: 133-138 [PMID: 25382113 DOI: 10.1111/hel.12184]

27 **Al-Hussaini AA**, Al Jurayyan AN, Bashir SM, Alshahrani D. Where are we today with *Helicobacter pylori* infection among healthy children in Saudi Arabia? *Saudi J Gastroenterol* 2019; **25**: 309-318 [PMID: 31006713 DOI: 10.4103/sjg.SJG\_531\_18]

28 **Jones NL**, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M; ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). *J Pediatr Gastroenterol Nutr* 2017; **64**: 991-1003 [PMID: 28541262 DOI: 10.1097/MPG.0000000000001594]

29 **Dimitrov G**, Gottrand F. Does gastric atrophy exist in children? *World J Gastroenterol* 2006; **12**: 6274-6279 [PMID: 17072948 DOI: 10.3748/wjg.v12.i39.6274]

30 **Villarreal-Calderon R**, Luévano-González A, Aragón-Flores M, Zhu H, Yuan Y, Xiang Q, Yan B, Stoll KA, Cross JV, Iczkowski KA, Mackinnon AC Jr. Antral atrophy, intestinal metaplasia, and preneoplastic markers in Mexican children with Helicobacter pylori-positive and Helicobacter pylori-negative gastritis. *Ann Diagn Pathol* 2014; **18**: 129-135 [PMID: 24656654 DOI: 10.1016/j.anndiagpath.2014.02.003]

31 **Kato S**, Kikuchi S, Nakajima S. When does gastric atrophy develop in Japanese children? *Helicobacter* 2008; **13**: 278-281 [PMID: 18665937 DOI: 10.1111/j.1523-5378.2008.00611.x]

32 **Boukthir S**, Mrad SM, Kalach N, Sammoud A. Gastric atrophy and Helicobacter pylori infection in children. *Trop Gastroenterol* 2009; **30**: 107-109 [PMID: 19760998]

33 **Kalach N**, Papadopoulos S, Asmar E, Spyckerelle C, Gosset P, Raymond J, Dehecq E, Decoster A, Creusy C, Dupont C. In French children, primary gastritis is more frequent than Helicobacter pylori gastritis. *Dig Dis Sci* 2009; **54**: 1958-1965 [PMID: 19003529 DOI: 10.1007/s10620-008-0553-y]

34 **Carvalho MA**, Machado NC, Ortolan EV, Rodrigues MA. Upper gastrointestinal histopathological findings in children and adolescents with nonulcer dyspepsia with Helicobacter pylori infection. *J Pediatr Gastroenterol Nutr* 2012; **55**: 523-529 [PMID: 22684348 DOI: 10.1097/MPG.0b013e3182618136]

35 **Xue Y**, Zhou LY, Lu HP, Liu JZ. Recurrence of Helicobacter pylori infection: incidence and influential factors. *Chin Med J (Engl)* 2019; **132**: 765-771 [PMID: 30897591 DOI: 10.1097/CM9.0000000000000146]

36 **Hu Y**, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. *Aliment Pharmacol Ther* 2017; **46**: 773-779 [PMID: 28892184 DOI: 10.1111/apt.14319]

37 **Kim MS**, Kim N, Kim SE, Jo HJ, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JM, Jung HC. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. *Helicobacter* 2013; **18**: 135-142 [PMID: 23066652 DOI: 10.1111/hel.12018]

38 **Sari YS**, Can D, Tunali V, Sahin O, Koc O, Bender O. H pylori: Treatment for the patient only or the whole family? *World J Gastroenterol* 2008; **14**: 1244-1247 [PMID: 18300351 DOI: 10.3748/wjg.14.1244]

39 **Shiotani A**, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. *Semin Cancer Biol* 2013; **23**: 492-501 [PMID: 23876852 DOI: 10.1016/j.semcancer.2013.07.004]

40 **Rugge M**, Genta RM, Di Mario F, El-Omar EM, El-Serag HB, Fassan M, Hunt RH, Kuipers EJ, Malfertheiner P, Sugano K, Graham DY. Gastric Cancer as Preventable Disease. *Clin Gastroenterol Hepatol* 2017; **15**: 1833-1843 [PMID: 28532700 DOI: 10.1016/j.cgh.2017.05.023]

41 **Raymond J**, Thiberg JM, Chevalier C, Kalach N, Bergeret M, Labigne A, Dauga C. Genetic and transmission analysis of Helicobacter pylori strains within a family. *Emerg Infect Dis* 2004; **10**: 1816-1821 [PMID: 15504269 DOI: 10.3201/eid1010.040042]

42 **Abadi ATB**. Strategies used by *helicobacter pylori* to establish persistent infection. *World J Gastroenterol* 2017; **23**: 2870-2882 [PMID: 28522905 DOI: 10.3748/wjg.v23.i16.2870]

43 **Ding SZ**, Goldberg JB, Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. *Future Oncol* 2010; **6**: 851-862 [PMID: 20465395 DOI: 10.2217/fon.10.37]

44 **Ding SZ**, Zheng PY. Helicobacter pylori infection induced gastric cancer; advance in gastric stem cell research and the remaining challenges. *Gut Pathog* 2012; **4**: 18 [PMID: 23217022 DOI: 10.1186/1757-4749-4-18]

45 **Sigal M**, Rothenberg ME, Logan CY, Lee JY, Honaker RW, Cooper RL, Passarelli B, Camorlinga M, Bouley DM, Alvarez G, Nusse R, Torres J, Amieva MR. Helicobacter pylori Activates and Expands Lgr5(+) Stem Cells Through Direct Colonization of the Gastric Glands. *Gastroenterology* 2015; **148**: 1392-404.e21 [PMID: 25725293 DOI: 10.1053/j.gastro.2015.02.049]

46 **Hayakawa Y**, Fox JG, Wang TC. The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models. *Cell Mol Gastroenterol Hepatol* 2017; **3**: 331-338 [PMID: 28462375 DOI: 10.1016/j.jcmgh.2017.01.013]

47 **Amieva M**, Peek RM Jr. Pathobiology of Helicobacter pylori-Induced Gastric Cancer. *Gastroenterology* 2016; **150**: 64-78 [PMID: 26385073 DOI: 10.1053/j.gastro.2015.09.004]

48 **Knorr J**, Ricci V, Hatakeyama M, Backert S. Classification of Helicobacter pylori Virulence Factors: Is CagA a Toxin or Not? *Trends Microbiol* 2019; **27**: 731-738 [PMID: 31130493 DOI: 10.1016/j.tim.2019.04.010]

49 **Ohnishi N**, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, Yamada G, Azuma T, Hatakeyama M. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. *Proc Natl Acad Sci U S A* 2008; **105**: 1003-1008 [PMID: 18192401 DOI: 10.1073/pnas.0711183105]

50 **Franco AT**, Johnston E, Krishna U, Yamaoka Y, Israel DA, Nagy TA, Wroblewski LE, Piazuelo MB, Correa P, Peek RM Jr. Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. *Cancer Res* 2008; **68**: 379-387 [PMID: 18199531 DOI: 10.1158/0008-5472.CAN-07-0824]

51 **Matos JI**, de Sousa HA, Marcos-Pinto R, Dinis-Ribeiro M. Helicobacter pylori CagA and VacA genotypes and gastric phenotype: a meta-analysis. *Eur J Gastroenterol Hepatol* 2013; **25**: 1431-1441 [PMID: 23929249 DOI: 10.1097/MEG.0b013e328364b53e]

52 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]

53 **Matsuo T**, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. *Helicobacter* 2011; **16**: 415-419 [PMID: 22059391 DOI: 10.1111/j.1523-5378.2011.00889.x]

54 **Stubljar D**, Jukic T, Ihan A. How far are we from vaccination against Helicobacter pylori infection? *Expert Rev Vaccines* 2018; **17**: 935-945 [PMID: 30238819 DOI: 10.1080/14760584.2018.1526680]

**Footnotes**

**Conflict-of-interest statement:** The author declares no conflicts of interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** November 14, 2019

**First decision:** December 4, 2019

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A, A

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Limpakan S, Syam AF, Talebi Bezmin Abadi A, Yücel O **S-Editor:** Yan JP **L-Editor:** Filipodia **E-Editor:** Zhang YL

**Figure Legends**



**Figure 1 Flow chart of whole family-based *Helicobacter pylori* infection management strategy.** In a typical gastroenterology clinic, visiting patients are questioned for symptoms and signs, and *Helicobacter pylori* (*H. pylori*) infection is tested. If the patient is *H. pylori* positive, the related family members are recommended to test *H. pylori* either by serological, stool antigen or urease breath tests, or both; this could include parents, spouses, children, or other members living in the same household. The infected family members are recommended to treat the infection, ideally at the same time, and follow up. If patients are confirmed as *H. pylori* negative, just following up without treatment is required. 1Screen test for family members can be urease breath tests, or various antibody tests. *H. pylori*: *Helicobacter pylori*.

**Table 1 Traditional and suggested *Helicobacter pylori* infection management strategies1**

|  |  |
| --- | --- |
| **Name of strategies** | **Character of the strategies and their applications** |
| 1 Test and treat1 | Recommended for young patients with uninvestigated dyspepsia, but not applicable to patients with alarm symptoms or older patients  Cost-effective or suitable only for low infection rate areas or counties  Not suitable for high infection- and gastric cancer-prevalent areas  Targeting *H. pylori*-infected individual, community or population-based |
| 2 Screen and treat1 | Recommended for patients with family history of gastric cancer, having alarm symptoms  May not be cost-effective for low infection rate areas or counties  Suitable for high infection- or gastric cancer-prevalent areas  Targeting *H. pylori*-infected individual-, community- or population-based |
| 3 Whole family-based | High-risk population-oriented, good patient-family compliance  Screen, identify, treat and follow up on all *H. pylori*-infected individuals in the entire family  Practical or suitable for both high and low *H. pylori*-infected areas or countries  Targeting all *H. pylori*-infected individuals in a whole family, no need to differentiate high- or low-infection rate areas or populations, whole family-based |

1Management strategies is based upon: Management of *Helicobacter pylori* infection-the Maastricht V/Florence Consensus Report[1]; *Helicobacter pylori* management in ASEAN: The Bangkok consensus report[9]; Fifth Chinese national consensus report on the management of *Helicobacter pylori* infection[10]; Guidelines for the management of *Helicobacter pylori* infection in Japan: 2016 revised edition[12]. *H. pylori*: *Helicobacter pylori*.

**Table 2 Common *Helicobacter pylori* intra-familial transmission routes1 and their prevention**

|  |  |  |
| --- | --- | --- |
| **Common routes** | **Infection routes** | **Prevention** |
| 1 Oral-oral | Sharing food from same dish, chewing food, feeding, wet kissing, consuming contaminated meat, milk, vegetable, water or food, poor hygiene practice | Avoid using same dish, consume healthy and safe food |
| 2 Shared utensils | Sharing food ware, dental equipment, *etc.* | Clean food ware and using safe dental equipment |
| 3 Fecal-oral | Consuming fecal contaminated water or food, such as well water, untreated water, *etc.* | Consume only safe food and water |
| 4 Outside family | Iatrogenic contamination, intimate contact with *H. pylori*-infected persons or utensils | Sterilize iatrogenic equipment and avoid intimate contact with *H. pylori*-infected persons and suspected utensils |

1For common *Helicobacter pylori* intra-familial transmission routes[14,16-22]. *H. pylori*: *Helicobacter pylori*.